Endava plc Reports Significant Swing to Net Loss Amidst Revenue Decline
summarizeSummary
Endava plc reported a significant swing to a net loss for the six months ended December 31, 2025, alongside a decline in revenue and gross profit, indicating substantial operational deterioration.
check_boxKey Events
-
Swing to Net Loss
The company reported a net loss of £15.063 million for the six months ended December 31, 2025, a significant reversal from a net profit of £9.098 million in the same period last year.
-
Revenue Decline
Revenue decreased by 7.26% to £362.285 million, down from £390.641 million in the prior year period.
-
Gross Profit Deterioration
Gross profit fell by 19.65% to £75.266 million, compared to £93.677 million in the previous year, indicating significant margin pressure.
-
Share Repurchases
The company repurchased £24.985 million of its own shares during the period, and an additional 487,677 shares between January 1, 2026, and the filing date.
auto_awesomeAnalysis
Endava plc's interim financial results for the six months ended December 31, 2025, reveal a substantial deterioration in performance. The company swung from a net profit of £9.098 million in the prior year to a net loss of £15.063 million, driven by a 7.26% decline in revenue and a nearly 20% drop in gross profit. This indicates significant operational challenges and margin pressure. While the company affirmed its ability to continue as a going concern and engaged in share repurchases, these positive signals are largely overshadowed by the core profitability issues. The market is likely to react negatively to these results, especially given the stock is trading near its 52-week low, suggesting investor concern about the company's ability to reverse these trends.
At the time of this filing, DAVA was trading at $4.30 on NYSE in the Technology sector, with a market capitalization of approximately $243.9M. The 52-week trading range was $4.21 to $21.81. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.